REGN vs. TECH: Regeneron Pharmaceuticals vs. Bio-Techne Stock Comparison

November 11, 2026

How do Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but REGN is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Profile Item	REGN	TECH
Name	Regeneron Pharmaceuticals, Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	93.55 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 2, 1991	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

REGN

TECH

GSPC

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Total Return (1Y)	40.87%	27.56%
Total Return (3Y, Annualized)	5.15%	9.11%
Total Return (5Y, Annualized)	8.58%	-9.91%

Risk Profile

Drawdown History

REGN

TECH

GSPC

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Volatility (1Y, Annualized)	34.08%	43.08%
Beta (5Y)	0.10	1.26
Max Drawdown (5Y)	-59.69%	-65.87%
Avg. Volume (3M)	772.95K	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

REGN and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Sharpe Ratio (1Y)	1.07	0.54
Sortino Ratio (1Y)	1.70	0.82

Profitability

ROE (TTM)

Both Regeneron Pharmaceuticals (REGN) at 14.95% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.95%

Max: 109.18%
REGN: 14.95%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 28.51% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.51%

REGN: 28.51%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Regeneron Pharmaceuticals (REGN) at 40.46% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.46%

Max: 83.12%
REGN: 40.46%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
ROE (TTM)	14.95%	8.33%
ROA (TTM)	7.59%	6.38%
Net Margin (TTM)	28.51%	14.00%
Operating Margin (TTM)	40.46%	12.21%
Gross Margin (TTM)	46.73%	66.23%

Growth

Revenue Growth

Both Regeneron Pharmaceuticals (REGN) at 0.99% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Regeneron Pharmaceuticals (REGN) at 8.19% is closer to the peer norm — faster per-share earnings growth for TECH.

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Revenue Growth (YoY)	0.99%	-0.38%
Revenue Growth (3Y CAGR)	5.62%	2.25%
EPS Growth (YoY)	8.19%	152.17%
EPS Growth (3Y CAGR)	2.77%	-12.97%

Financial Strength

Current Ratio (MRQ)

Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.35

Max: 25.13
Q3: 12.13
Median: 5.52
REGN: 3.35
Q1: 2.47
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Regeneron Pharmaceuticals (REGN) at 0.08 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.08

Max: 1.42
Q3: 0.65
Median: 0.15
REGN: 0.08
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Current Ratio (MRQ)	3.35	2.28
Debt / Equity (MRQ)	0.08	0.13
Net Debt / EBITDA	-1.17	-0.20

Dividends

Dividend Yield (TTM)

Both Regeneron Pharmaceuticals (REGN) at 0.41% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41%

REGN: 0.41%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Regeneron Pharmaceuticals (REGN) at 8.18% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.18%

REGN: 8.18%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
Dividend Yield (TTM)	0.41%	0.44%
Dividend Payout Ratio (TTM)	8.18%	27.59%

Valuation

P/E Ratio (TTM)

Regeneron Pharmaceuticals (REGN) at 19.99 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.99

Max: 85.34
Q3: 43.46
Median: 26.69
REGN: 19.99
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Regeneron Pharmaceuticals (REGN) at 5.54 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.54

Max: 58.18
Q3: 25.77
Median: 7.30
REGN: 5.54
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Regeneron Pharmaceuticals (REGN) at 2.71 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

REGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.71

Max: 13.53
Q3: 6.54
Median: 3.25
REGN: 2.71
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Regeneron Pharmaceuticals (REGN) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Regeneron Pharmaceuticals (REGN) and Bio-Techne (TECH)
Metric	REGN	TECH
P/E Ratio (TTM)	19.99	62.74
P/S Ratio (TTM)	5.54	9.31
P/B Ratio (MRQ)	2.71	5.28
Free Cash Flow Yield (TTM)	2.76%	2.39%